Literature DB >> 16914238

High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production.

V Barban1, Y Girerd, M Aguirre, S Gulia, F Pétiard, P Riou, B Barrere, J Lang.   

Abstract

We have retrospectively analyzed 12 bulk lots of yellow fever vaccine Stamaril, produced between 1990 and 2002 and prepared from the same seed lot that has been in continuous use since 1990. All vaccine batches displayed identical genome sequence. Only four nucleotide substitutions were observed, compared to previously published sequence, with no incidence at amino-acid level. Fine analysis of viral plaque size distribution was used as an additional marker for genetic stability and demonstrated a remarkable homogeneity of the viral population. The total virus load, measured by qRT-PCR, was also homogeneous pointing out reproducibility of the vaccine production process. Mice inoculated intracerebrally with the different bulks exhibited a similar average survival time, and ratio between in vitro potency and mouse LD(50) titers remained constant from batch-to-batch. Taken together, these data demonstrate the genetic stability of the strain at mass production level over a period of 12 years and reinforce the generally admitted idea of the safety of YF17D-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914238     DOI: 10.1016/j.vaccine.2006.06.082

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past.

Authors:  Rashedul Islam; Mohammed Salahuddin; Md Salahuddin Ayubi; Tahmina Hossain; Apurba Majumder; Andrew W Taylor-Robinson; Abdullah Mahmud-Al-Rafat
Journal:  Virol Sin       Date:  2015-10-20       Impact factor: 4.327

2.  Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories.

Authors:  Cristina Domingo; Pranav Patel; Jasmin Yillah; Manfred Weidmann; Jairo A Méndez; Emmanuel Rivalyn Nakouné; Matthias Niedrig
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

3.  Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

Authors:  Irina Tretyakova; Brian Nickols; Rachmat Hidajat; Jenny Jokinen; Igor S Lukashevich; Peter Pushko
Journal:  Virology       Date:  2014-08-16       Impact factor: 3.616

4.  Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.

Authors:  Enoch Muyanja; Aloysius Ssemaganda; Pearline Ngauv; Rafael Cubas; Helene Perrin; Divya Srinivasan; Glenda Canderan; Benton Lawson; Jakub Kopycinski; Amanda S Graham; Dawne K Rowe; Michaela J Smith; Sharon Isern; Scott Michael; Guido Silvestri; Thomas H Vanderford; Erika Castro; Giuseppe Pantaleo; Joel Singer; Jill Gillmour; Noah Kiwanuka; Annet Nanvubya; Claudia Schmidt; Josephine Birungi; Josephine Cox; Elias K Haddad; Pontiano Kaleebu; Patricia Fast; Rafick-Pierre Sekaly; Lydie Trautmann; Denis Gaucher
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

Review 5.  Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Stephen J Seligman; James S Robertson; Bruno Guy; Edward B Hayes; Richard C Condit; Jean Louis Excler; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2014-10-27       Impact factor: 3.641

6.  Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.

Authors:  Xiaohong Jiang; Tim J Dalebout; Peter J Bredenbeek; Ricardo Carrion; Kathleen Brasky; Jean Patterson; Marco Goicochea; Joseph Bryant; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2010-12-08       Impact factor: 3.641

7.  Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing.

Authors:  Andrew Beck; Robert B Tesh; Thomas G Wood; Steven G Widen; Kate D Ryman; Alan D T Barrett
Journal:  J Infect Dis       Date:  2013-10-17       Impact factor: 5.226

8.  New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters.

Authors:  Alice G Fernandes-Monteiro; Gisela F Trindade; Anna M Y Yamamura; Otacilio C Moreira; Vanessa S de Paula; Ana Cláudia M Duarte; Constança Britto; Sheila Maria B Lima
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 9.  Advanced vaccine candidates for Lassa fever.

Authors:  Igor S Lukashevich
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

Review 10.  Current progress in dengue vaccines.

Authors:  Shu-Wen Wan; Chiou-Feng Lin; Shuying Wang; Yu-Hung Chen; Trai-Ming Yeh; Hsiao-Sheng Liu; Robert Anderson; Yee-Shin Lin
Journal:  J Biomed Sci       Date:  2013-06-13       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.